The FDA has granted priority review status to Chinese pharma company BeiGene for its application for Brukinsa, or zanubrutinib, a treatment for pretreated marginal zone lymphoma. The submission is supported by data from the company's midstage MAGNOLIA trial.
FDA grants priority review for zanubrutinib for MZL
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.